NeuBase Therapeutics Inc expected to post a loss of 22  cents a share - Earnings Preview

NeuBase Therapeutics

10/05/2021 12:04

* NeuBase Therapeutics Inc  NBSE.OQ   NBSE.O  is expected
to show a no change in quarterly revenue when it reports
results on May 12 (estimated) .
​* Refinitiv's mean analyst estimate for NeuBase Therapeutics
Inc is for a loss of 22 cents per share. For the same quarter
last year, the company reported a loss of 26 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $17​, about 69% above​ its last closing
price of $5.27. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.23       -0.23      -0.18     Beat    21.7
 Sep. 30 2020              -0.20      -0.19     Beat    4.2
 Jun. 30 2020  -0.23       -0.23      -0.18     Beat    20.6​
 Mar. 31 2020  -0.22       -0.22      -0.26     Missed  -16.9
 Dec.          -0.37​      -0.32      -0.26     Beat    18.1​
 31​ 2019​                                              
 Sep. 30 2019  -0.27       -0.28      -2.14     Missed  -673.5
                                                        ​
 This summary was machine generated May 10 at 11:04 GMT.  All
figures in US dollars unless otherwise stated